

Date: July 31, 2026
To
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

Scrip Code: **532041**

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on Friday, July 31, 2026 as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015[“SEBI(LODR), 2015”]

Pursuant to Regulation 30 and other applicable Regulations of SEBI (LODR), 2015, the Board of Directors of the Company in its meeting held today i.e., on July 31, 2026:


1. Approved the Un-Audited Standalone Financial Results of the Company for the first quarter ended June 30, 2026, along with the Limited Review Report issued by the Statutory Auditors thereon.
2. Considered and approved the Notice convening the 34th Annual General Meeting (AGM) of the Company, along with the Directors' Report and Corporate Governance Report for the financial year ended March 31, 2026.
3. Fixed the date, time and venue of the 34th AGM as Wednesday, September 30, 2026, at 10:00 A.M., to be held at the Registered Office of the Company.
4. Appointed Mr. VBSS Prasad, Practicing Company Secretary, as Scrutinizer for conducting the remote e-voting process and voting at the venue of the 34th AGM, in a fair and transparent manner.

Further, pursuant to Regulation 30 of SEBI (LODR), 2015 and the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023(including any statutory modification(s) or amendment(s) or re-enactment(s) thereof, for the time being in force):

The meeting commenced at 02:00 P.M. and concluded at **03-40 PM**

This is for your information and records.

Thanking You,
For Hindustan Bio Sciences Limited


J V R Mohan Raju
Managing Director
DIN: 00060800



HINDUSTAN BIOSCIENCES LTD.

#31, Sagar Society, Road No. 2,
Banjara Hills, Hyderabad - 500 034, INDIA.

+91 40 23555161 / 23555181
pharma.hindustanbio@gmail.com
www.hindustan.bio
CIN : L26942TG1991PLC013564


STATEMENT OF UN- AUDITED RESULTS FOR THE QUARTER ENDED ON 30TH JUNE,2026


Sl. No.	Particulars	Quarter ended		Rs. In Lakhs	
		30-06-2026 (unaudited)	31.03.2026 (Audited)	30-06-2025 (unaudited)	31.03.2026 (Audited)
1	Income from Operations				
	(a) Revenue from operations	0.00	0.00	32.19	73.71
	(b) Other Income	0.00	0.02	1.31	0
	Total Revenue (1)	-	0.02	33.50	73.71
2	Expenses				
	(a) cost of material consumed	-	-	-	-
	(b) Purchases of Stock -in-trade	0.00	0.00	21.19	44.90
	(c) Changes in Inventories of finished goods,Stock - in-Trade and Work-in-Progress	-	-	-	-
	(d) Employee Benefit Expenses	5.72	4.96	4.40	19.35
	(e) Finance Costs	0.00	0.00	0.05	0.11
	(f) Selling Expenses	0.01	0.00	0.15	0.00
	(g) Depreciation and amortisation Expenses	0.00	0.42	0.00	1.99
	(h) Other Expenses	5.56	6.30	6.32	15.29
	Total Expenses(2)	11.29	11.68	32.11	81.64
3	Profit/(Loss) before Exceptional& Extraordinary items and tax (1 -2)	(11.29)	(11.66)	1.40	(7.93)
4	Exceptional items	-	-	-	-
5	Profit/(Loss) before tax(3 -4)	(11.29)	(11.66)	1.40	(7.93)
6	Tax Expenses				
	(a) Current Tax	-	-	-	-
	(b) Previous Taxes	-	-	-	-
	(b) Deferred Tax	0	0	0	(0.03)
7	Profit /(Loss) for the period from continuing operations(5-6)	(11.29)	(11.66)	1.40	(7.89)
8	Profit /(Loss) from discontinued operations	-	-	-	-
9	Tax Expense of discontinued operations	-	-	-	-
10	Profit /Loss from Discontinued operations after tax(8-9)	-	-	-	-
11	Profit/(Loss) for the period(7+10)	(11.29)	(11.66)	1.40	(7.89)
12	Other Comprehensive Income				
	A (1) Items that will not be reclassified to profit or loss	-	-	-	-
	(2) Income tax relating to items that will not be re- classified to profit or loss	-	-	-	-
	B (1) Items that will be reclassified to profit or loss	-	-	-	-
	(2) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
13	Total Comprehensive Income for the period (11+12) (comprising Profit (Loss) and other comprehensive income for the period	(11.29)	(11.66)	1.40	(7.89)
14	Paid up Equity Capital(Face value of Rs. 2/- each)	205.02	205.02	205.02	205.02
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				(122.42)
16	Earnings per equity share for continuing operations				
	(A) Basic	(0.11)	(0.11)	0.01	(0.08)
	(B) Diluted	(0.11)	(0.11)	0.01	(0.08)
17	Earnings per equity share for discontinuing operations				
	(A) Basic	-	-	-	-
	(B) Diluted	-	-	-	-
18	Earnings per equity share(for discontinuing & continuing operations				
	(A) Basic	(0.11)	(0.11)	0.01	(0.08)
	(B) Diluted	(0.11)	(0.11)	0.01	(0.08)

Notes:

- The above standalone results for the quarter ended 30th June 2026 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 31st July 2026. The statutory auditors have expressed an unmodified audit opinion.
- This statement is as per regulation 33 of the SEBI (LODR) Regulations, 2015.
- The Company operates in one reportable business segment i.e., Trading of Pharmaceuticals. Hence segmental reporting as per Ind AS 108 is not applicable.
- The results for the Quarter ended 30th June, 2026 are also available on the website of BSE Limited and on the Company's website.
- Figures for the previous periods have been rearranged/reclassified wherever necessary to conform to the current period presentation.

Place: Hyderabad
Date: 31-07-2026


V R Mohan Reddy
Managing Director
(DIN: 00060800)





VASG & ASSOCIATES
Chartered Accountants

503/A, 5th Floor, Kubera Towers,
Narayanaguda, Hyderabad - 500 029.
Ph : 040-66849660
E-mail : info@vasg-ca.com
vasgassociates@gmail.com

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
STANDALONE FINANCIAL RESULTS**

TO THE BOARD OF DIRECTORS OF

M/S HINDUSTAN BIO SCIENCES LIMITED

We have reviewed the accompanying statement of unaudited financial results of **M/S. HINDUSTAN BIOSCIENCES LIMITED** (the "Company"), for the quarter ended June 30, 2026, being prepared by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

The preparation of this statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India is the responsibility of the company's management and has been approved by the Board of Directors of the company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "**Review of Interim Financial Information Performed by the Independent Auditor of the Entity**", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VASG & ASSOCIATES
Chartered Accountants
FRNo.006070S



A.Viswanatha Rao
(Partner)

M.No:029597

UDIN: 26029597OLIIBY7540

Date:31.07.2026

Place:Hyderabad